Unresectable Gastroesophageal Junction Adenocarcinoma Recruiting Phase 3 Trials for Oxaliplatin (DB00526)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05677490mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaTreatment